RNAZ Stock: Why It Substantially Increased Today like 53% | RNAZ Stock NEWS

RNAZ Stock: Why It Substantially Increased Today



The stock price of TransCode Therapeutics, Inc. (Nasdaq: RNAZ) is trading at over 75% during intraday trading today. This is why it happened.
The stock price of TransCode Therapeutics, Inc. (Nasdaq: RNAZ) – an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics – is trading at over 75% during intraday trading today. Investors are responding positively to TransCode Therapeutics announcing that preclinical research supporting its lead candidate TTX-MC138 was published in Cancer Nanotechnology.



The article — “Radiolabeling and PET-MRI microdosing of the experimental cancer therapeutic, MN-anti-miR10b, demonstrates delivery to metastic lesions in a murine model of metastatic breast cancer” — resulted from research conducted at the Athinoula A. Martinos Center for Biomedical Imaging in the Department of Radiology at Massachusetts General Hospital and Harvard Medical School. And this preclinical study developed a radio-labeled derivative of TTX-MC138 (referenced as MN-anti-miR10b) tagged with Cu-64 — enabling highly sensitive and specific quantitative determination of its pharmacokinetics and biodistribution as well as observation of delivery to metastases via noninvasive positron emission tomography-magnetic resonance imaging (PET-MRI).

The key results of the study demonstrated that TTX-MC138 — when injected intravenously, accumulated in metastatic lesions. And these results suggest that TransCode’s TTX platform delivers its therapeutic candidate as intended and the company believes supports clinical evaluation of TTX-MC138. Plus the investigation describes the development of a microdosing PET-MRI approach that could potentially be used for measurement of TTX-MC138 biodistribution in cancer patients and its delivery to clinical metastases.


The capacity to carry out microdosing PET studies in patients under an exploratory investigational new drug application protocol would represent an important step on the path to clinical translation because it could facilitate and expedite approval from the U.S. Food and Drug Administration (FDA) for initial human studies.

TransCode is expecting to file an exploratory investigational new drug (eIND) application for TTX-MC138 in the first quarter of 2022 to support a Phase 0 study in patients with metastatic cancer. And under an eIND, FDA approval may be obtained more quickly and at lower cost than with a traditional IND for therapeutic agents.